NIH Reporter #5R01CA301727-02

NIH Grant for Microbiome-Derived Immunomodulatory Microproteins in Cancer Immunotherapy

This opportunity is a research grant solicitation from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), focused on microbiome-derived immunomodulatory microproteins for cancer immunotherapy. - Government Buyer: - National Cancer Institute (NCI), NIH - Project based at Stanford University, Santa Clara County, California - Scope and Requirements: - Research grant titled 'Mining the microbiome for immunomodulatory microproteins' - Targeted at schools of medicine, specifically departments of internal medicine - Objective: Identify microbial microproteins that modulate macrophage function to enhance cancer treatment efficacy - Emphasis on microbiome research and cancer immunotherapy - No cost extension restrictions - No specified liquidated damages - OEMs and Vendors: - No specific OEMs or vendors are mentioned, as this is a research grant, not a procurement of goods - Products/Services Requested: - No commercial products or part numbers requested; focus is on research deliverables - Notable Requirements: - Applicants must review the grant guidance document for detailed application instructions - Project duration is five years with no option years or annual subscription - Estimated grant value is $640,554

Description

This is a research grant opportunity focused on microbiome research related to cancer immunotherapy. The project aims to identify microbial microproteins that modulate macrophage function to enhance cancer treatment efficacy. The grant is offered by the National Cancer Institute (NCI), part of NIH, and is active and open for applications. The project duration is from May 1, 2025, to April 30, 2030, with an estimated value of $640,554. Applicants should review the provided grant guidance document for detailed application instructions.

View original listing